3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
30
Neoplasms
11
Sarcoma
8
Carcinoma, Non-Small-Cell Lung
8
Breast Neoplasms
7
Ovarian Neoplasms
6
Neoplasm Metastasis
5
Fallopian Tube Neoplasms
3
Colorectal Neoplasms
3
Recurrence
2
Hemangiosarcoma
2
Financial Stress
2
Clear-cell metastatic renal cell carcinoma
2
Carcinoma, Ovarian Epithelial
2
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Uterine Cervical Diseases
1
Solid Tumours
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Prostatic Neoplasms
1
Patient Preference
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms, Plasma Cell
1
Melanoma
1
Liver Neoplasms
1
Leiomyosarcoma
1
Interventions
pertuzumab
1
pazopanib
1
decitabine and cedazuridine drug combination
1
daratumumab
1
Trastuzumab
1
Surgical Procedures, Operative
1
Sunitinib
1
Sorafenib
1
Radiotherapy
1
Opdualag
1
Nivolumab
1
Injections, Subcutaneous
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Patient Preference
×
pazopanib
×
Clear all
NCT01064310
2017-04-17
PISCES
Novartis
Phase 3
Completed
169 enrolled
16 charts